We are live on
!
Find out more
LP
Longaeva Partners Portfolio holdings
AUM
$2.7B
1-Year Est. Return
37.16%
This Fund
S&P 500
This Quarter
Est. Return
-3.4%
1 Year Est. Return
+37.16%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.7B
AUM Growth
+$1.51B
(+127%)
Cap. Flow
+$1.75B
Cap. Flow
% of AUM
64.98%
Top 10 Holdings %
Top 10 Hldgs %
35.87%
Holding
269
New
150
Increased
33
Reduced
19
Closed
65
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bank of America
BAC
|
+$80.3M |
| 2 |
Boston Scientific
BSX
|
+$76.6M |
| 3 |
KeyCorp
KEY
|
+$62.3M |
| 4 |
Goldman Sachs
GS
|
+$60.3M |
| 5 |
MMED
MiniMed Group Inc
MMED
|
+$52.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CAI
Caris Life Sciences
CAI
|
+$40.7M |
| 2 |
Becton Dickinson
BDX
|
+$25.5M |
| 3 |
TPG
TPG
|
+$23.9M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$22.6M |
| 5 |
Edwards Lifesciences
EW
|
+$22.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 31.18% |
| 2 | Healthcare | 16.78% |
| 3 | Technology | 12.09% |
| 4 | Industrials | 6.84% |
| 5 | Consumer Discretionary | 6.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Southwest Airlines
LUV
$22.1B
| $5.81M | 0.22% |
+154,535
| New | +$6.98M |
|
102
GE Vernova
GEV
$270B
| $5.55M | 0.21% |
+6,354
| New | +$4.96M |
|
103
GDS Holdings
GDS
$6.34B
| $5.47M | 0.2% |
+135,882
| New | +$5.83M |
|
104
UnitedHealth
UNH
$382B
| $5.41M | 0.2% |
20,000
-10,967
| -35% | -$3.27M |
|
105
CALL
DraftKings
DKNG
$11.4B
| $5.41M | 0.2% |
+250,000
| New | +$6.77M |
|
|
BLTE
106
Belite Bio
BLTE
$6.15B
| $5.34M | 0.2% |
+33,492
| New | +$5.63M |
|
107
Carnival Corporation Ltd
CCL
$36.1B
| $5.31M | 0.2% |
205,000
-27,869
| -12% | -$813K |
|
108
Wells Fargo
WFC
$261B
| $5.08M | 0.19% |
+63,780
| New | +$5.48M |
|
109
Banc of California
BANC
$3.28B
| $5.02M | 0.19% |
+285,796
| New | +$5.45M |
|
110
Walmart Inc
WMT
$871B
| $4.97M | 0.18% |
+40,000
| New | +$4.91M |
|
111
Trane Technologies
TT
$106B
| $4.87M | 0.18% |
+11,689
| New | +$4.96M |
|
|
LMRI
112
Lumexa Imaging Holdings
LMRI
$1.05B
| $4.79M | 0.18% |
557,423
+357,423
| +179% | +$4.91M |
|
113
Ultragenyx Pharmaceutical
RARE
$2.65B
| $4.78M | 0.18% |
+228,107
| New | +$5.14M |
|
114
Relay Therapeutics
RLAY
$4.02B
| $4.68M | 0.17% |
+470,544
| New | +$4.21M |
|
|
YSS
115
York Space Systems
YSS
$2.24B
| $4.66M | 0.17% |
+210,000
| New | +$5.09M |
|
|
KYIV
116
Kyivstar Group
KYIV
$3.09B
| $4.64M | 0.17% |
+458,418
| New | +$5.43M |
|
|
ALH
117
Alliance Laundry Holdings
ALH
$5.09B
| $4.54M | 0.17% |
218,876
-20,884
| -9% | -$454K |
|
118
TJX Companies
TJX
$170B
| $4.52M | 0.17% |
+28,298
| New | +$4.41M |
|
119
Enliven Therapeutics
ELVN
$3.78B
| $4.43M | 0.16% |
+113,065
| New | +$3.13M |
|
120
Pentair
PNR
$10.2B
| $4.39M | 0.16% |
+50,411
| New | +$4.94M |
|
121
Procept Biorobotics
PRCT
$950M
| $4.38M | 0.16% |
+175,000
| New | +$4.93M |
|
122
Verastem
VSTM
$532M
| $4.28M | 0.16% |
+807,755
| New | +$4.98M |
|
123
Northrop Grumman
NOC
$77B
| $4.28M | 0.16% |
+6,271
| New | +$4.34M |
|
124
MasTec
MTZ
$26.7B
| $4.19M | 0.16% |
+13,014
| New | +$3.52M |
|
125
East-West Bancorp
EWBC
$17.9B
| $3.94M | 0.15% |
+36,913
| New | +$4.16M |
|
Similar funds
GIA
HCM
CI
LSA
HC
SCM
BCM
NB
Longaeva Partners's Q1 2026 Portfolio in Review
As of Q1 2026, Longaeva Partners held 269 positions worth $2.7B, up 127% from $1.19B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Longaeva Partners deployed $1.75B of net new capital in Q1 2026, opening 150 new positions and adding to 33 existing holdings. Its largest new stake was Bank of America: 1,555,661 shares worth $75.8M.
By sector, the portfolio is most concentrated in Financials at 31% of assets, up from 22% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Annexon, an estimated $14M trimmed.
- Longaeva Partners's largest Q1 2026 buy was Bank of America: 1,555,661 shares worth $75.8M.
- Longaeva Partners added most to PNC Financial Services in Q1 2026, an estimated $48M increase.
- Longaeva Partners's biggest Q1 2026 reduction was Annexon, cutting an estimated $14M.
- Longaeva Partners fully exited Caris Life Sciences in Q1 2026, selling an estimated $40.7M.
- Longaeva Partners's ten largest holdings make up 36% of its $2.7B portfolio in Q1 2026.
- Longaeva Partners opened 150 new positions and closed 65 in Q1 2026.
- Longaeva Partners's portfolio value rose 127% quarter-over-quarter to $2.7B.
Based on Longaeva Partners's 13F filing for Q1 2026, filed 15 May 2026.